All Stories

  1. A Novel Method for Cryopreservation of Human Neutrophils for Phenotypic Analysis
  2. Evaluating a Potential Dose-Sparing Self-Amplifying RNA Vaccine for Induction of Functional Antibodies to Blood-Stage <em>Plasmodium falciparum</em> Malaria
  3. Targeting a malaria merozoite surface protein with mRNA vaccine generates multifunctional antibodies
  4. A Novel Method for Cryopreservation of Human Neutrophils for Phenotypic Analysis
  5. An abundant merozoite surface protein of Plasmodium falciparum modulates susceptibility to inhibitory antibodies
  6. An abundant merozoite surface protein of Plasmodium falciparum modulates susceptibility to inhibitory antibodies
  7. First exposure to SARS-CoV-2 shapes IgG subclass switching after mRNA vaccination
  8. Antibody fine specificity correlates with protection from malaria for the RTS,S vaccine in young African children: A post hoc analysis of a phase IIb randomised controlled trial
  9. Antimicrobials for neonates: evaluation and prescribing practices in Australian neonatal units
  10. Relationship between antibody avidity, Fc-mediated functional activity and longevity of malaria vaccine responses in clinical trials
  11. Women’s perspectives on health service integration for multi-morbidity in pregnancy, childbirth, and postpartum in a high-burden setting
  12. Tracking children's immune responses reveals an antibody blueprint for fighting malaria
  13. Tfh2 and a subset of Tfh1 cells associate with antibody-mediated immunity to malaria
  14. Evaluation of whole blood CD64 for identifying infection in neonates receiving hospital care
  15. An abundant merozoite surface protein of Plasmodium falciparum modulates susceptibility to inhibitory antibodies
  16. Development of high affinity antibodies to Plasmodium falciparum merozoite and sporozoite antigens during infancy and adulthood
  17. Role of malaria exposure and off-target responses on RTS,S/AS02A vaccine immunogenicity and protection in Mozambican children
  18. Post-vaccination IgG4 and IgG2 class switch associates with increased risk of SARS-CoV-2 infections
  19. Plasmodium falciparum reticulocyte-binding homologues are targets of human inhibitory antibodies and play a role in immune evasion
  20. Antibody correlates of risk of clinical malaria in an area of low and unstable malaria transmission in western Kenya
  21. Functionally Distinct pTfh1 Subsets with Roles in Malaria-Specific Immunity
  22. Antimicrobials for Neonates: Practitioner Decisions and Diagnostic Certainty
  23. Detrimental infant and maternal outcomes of undiagnosed asymptomatic malaria in pregnancy
  24. IgM Is Prominent and Activates Complement in Acquired Transmission-Blocking Immunity Against Malaria
  25. Women's Perspectives on Health Service Integration Inform Strategies to Address Multi-Morbidity in Pregnancy, Childbirth and Postpartum in a High Burden Setting
  26. Induction of Fc-dependent functional antibodies against different variants of SARS-CoV-2 varies by vaccine type and prior infection
  27. Potent AMA1-specific human monoclonal antibody against Plasmodium vivax Pre-erythrocytic and Blood Stages
  28. Integrated Approaches for the Delivery of Maternal and Child Health Services with Childhood Immunization Programs in Low- and Middle-Income Countries: Systematic Review Update 2011–2020
  29. Heterogeneity of the human immune response to malaria infection and vaccination driven by latent cytomegalovirus infection
  30. Antibody mechanisms of protection against malaria in RTS,S-vaccinated children: a post-hoc serological analysis of phase 2 trial
  31. Mycoplasma genitalium in pregnancy, including specific co-infections, is associated with lower birthweight: A prospective cohort study
  32. A broadly cross-reactive i-body to AMA1 potently inhibits blood and liver stages of Plasmodium parasites
  33. IgM plays a prominent role in naturally acquired immunity against Plasmodium falciparum gametocytes
  34. Geospatial joint modeling of vector and parasite serology to microstratify malaria transmission
  35. Declining Antibody Affinity Over Time After Human Vaccination With a Plasmodium falciparum Merozoite Vaccine Candidate
  36. Heterogeneity of the human immune response to malaria infection and vaccination driven by latent cytomegalovirus infection
  37. Previous Malaria Exposures and Immune Dysregulation: Developing Strategies To Improve Malaria Vaccine Efficacy in Young Children
  38. A Diversity Covering (DiCo) Plasmodium vivax apical membrane antigen-1 vaccine adjuvanted with RFASE/RSL10 yields high levels of growth-inhibitory antibodies
  39. Potent AMA1-specific human monoclonal antibody against P. vivax Pre-erythrocytic and Blood Stages
  40. Potent AMA1-specific human monoclonal antibody against P. vivax Pre-erythrocytic and Blood Stages
  41. Clinical and immunological outcomes of HIV-exposed uninfected and HIV-unexposed uninfected children in the first 24 months of life in Western Kenya
  42. Complement detection on trophozoite stage Plasmodium falciparumparasites using flow cytometry or Western blot
  43. Plasmodium falciparum Growth or Invasion Inhibition Assays
  44. Antibody-dependent cell-mediated cytotoxicity (ADCC) assay with natural killer cells in malaria immunity
  45. Complement-fixation by antibodies to Plasmodium falciparum
  46. Isolation of viable Plasmodium falciparum merozoites
  47. Phagocytosis of antigen-coated beads or malaria parasites using neutrophils
  48. Quantifying antibody binding to Fcγ-receptors in malaria immunity
  49. Acquisition of complement fixing antibodies targeting Plasmodium falciparum merozoites in infants and their mothers in Uganda
  50. A step forward for Plasmodium falciparum malaria transmission-blocking vaccines
  51. Fc-dependent functional activity of ChAdOx1-S and CoronaVac vaccine-induced antibodies to the SARS-CoV-2 spike protein
  52. Associations between prenatal malaria exposure, maternal antibodies at birth, and malaria susceptibility during the first year of life in Burkina Faso
  53. Community perspectives and experiences of quality maternal and newborn care in East New Britain, Papua New Guinea
  54. The unfinished agenda of communicable diseases among children and adolescents before the COVID-19 pandemic, 1990–2019: a systematic analysis of the Global Burden of Disease Study 2019
  55. Quantifying differences in iron deficiency-attributable anemia during pregnancy and postpartum
  56. Clinical and Immunological Outcomes of HIV-Exposed Uninfected and HIV-Unexposed Uninfected Children in the First 24 Months of Life in Western Kenya
  57. Antibody to Plasmodium falciparum Variant Surface Antigens, var Gene Transcription, and ABO Blood Group in Children With Severe or Uncomplicated Malaria
  58. Unfractionated heparin versus enoxaparin for venous thromboembolism prophylaxis in intensive care units: a propensity score adjusted analysis
  59. Defining species-specific and conserved interactions of apical membrane protein 1 during erythrocyte invasion in malaria to inform multi-species vaccines
  60. Low knowledge of newborn danger signs among pregnant women in Papua New Guinea and implications for health seeking behaviour in early infancy – findings from a longitudinal study
  61. Corrigendum: Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2
  62. The direct binding of Plasmodium vivax AMA1 to erythrocytes defines a RON2-independent invasion pathway
  63. Targeting malaria parasites with novel derivatives of azithromycin
  64. The RTS,S malaria vaccine: Current impact and foundation for the future
  65. Asia-Pacific ICEMR: Understanding Malaria Transmission to Accelerate Malaria Elimination in the Asia Pacific Region
  66. Impact of Environmental Modifications on the Ecology, Epidemiology, and Pathogenesis of Plasmodium falciparum and Plasmodium vivax Malaria in East Africa
  67. Induction, decay, and determinants of functional antibodies following vaccination with the RTS,S malaria vaccine in young children
  68. Integrating de novo and inherited variants in 42,607 autism cases identifies mutations in new moderate-risk genes
  69. Assessment of IgG3 as a serological exposure marker for Plasmodium vivax in areas with moderate–high malaria transmission intensity
  70. Author Correction: Antibody responses to the RTS,S/AS01E vaccine and Plasmodium falciparum antigens after a booster dose within the phase 3 trial in Mozambique
  71. Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2
  72. Antibody dynamics in children with first or repeat Plasmodium falciparum infections
  73. Age-dependent changes in circulating Tfh cells influence development of functional malaria antibodies in children
  74. Comparison of Antibody Responses and Parasite Clearance in Artemisinin Therapeutic Efficacy Studies in the Democratic Republic of Congo and Asia
  75. Quality newborn care in East New Britain, Papua New Guinea: measuring early newborn care practices and identifying opportunities for improvement
  76. Induction, decay, and determinants of functional antibodies following vaccination with the RTS,S malaria vaccine in young children
  77. The Plasmodium falciparum parasitophorous vacuole protein P113 interacts with the parasite protein export machinery and maintains normal vacuole architecture
  78. Anti-Gametocyte Antigen Humoral Immunity and Gametocytemia During Treatment of Uncomplicated Falciparum Malaria: A Multi-National Study
  79. Quantification of the dynamics of antibody response to malaria to inform sero-surveillance in pregnant women
  80. Partnership-defined quality approach to companionship during labour and birth in East New Britain, Papua New Guinea: A mixed-methods study
  81. Adults with Plasmodium falciparum malaria have higher magnitude and quality of circulating T-follicular helper cells compared to children
  82. Age dependent changes in circulating Tfh cells influence the development of functional antibodies to malaria in children.
  83. Age dependent changes in circulating Tfh cells influence the development of functional antibodies to malaria in children
  84. Antibody Targets and Properties for Complement-Fixation Against the Circumsporozoite Protein in Malaria Immunity
  85. Multi-functional antibody profiling for malaria vaccine development and evaluation
  86. Recent clinical trials inform the future for malaria vaccines
  87. Reduced risk of placental parasitemia associated with complement fixation on Plasmodium falciparum by antibodies among pregnant women
  88. High Antibodies to VAR2CSA in Response to Malaria Infection Are Associated With Improved Birthweight in a Longitudinal Study of Pregnant Women
  89. Reduced risk of placental parasitaemia associated with complement fixation on Plasmodium falciparum by antibodies among pregnant women
  90. Community-based molecular and serological surveillance of subclinical malaria in Myanmar
  91. HIV infection and placental malaria reduce maternal transfer of multiple antimalarial antibodies in Mozambican women
  92. Mechanisms and targets of Fcγ-receptor mediated immunity to malaria sporozoites
  93. Novel Virus-Like Particle Vaccine Encoding the Circumsporozoite Protein of Plasmodium falciparum Is Immunogenic and Induces Functional Antibody Responses in Mice
  94. Framework for Characterizing Longitudinal Antibody Response in Children After Plasmodium falciparum Infection
  95. Mycoplasma genitalium and Other Reproductive Tract Infections in Pregnant Women, Papua New Guinea, 2015–2017
  96. Complement Factors in COVID-19 Therapeutics and Vaccines
  97. Impact of a Rapid Decline in Malaria Transmission on Antimalarial IgG Subclasses and Avidity
  98. Risk factors and knowledge associated with high unintended pregnancy rates and low family planning use among pregnant women in Papua New Guinea
  99. RTS,S/AS01E malaria vaccine induces IgA responses against CSP and vaccine-unrelated antigens in African children in the phase 3 trial
  100. Novel virus-like particle vaccine encoding the circumsporozoite protein ofPlasmodium falciparumis immunogenic and induces functional antibody responses
  101. Th2-like T Follicular Helper Cells Promote Functional Antibody Production during Plasmodium falciparum Infection
  102. Sero-epidemiological evaluation of malaria transmission in The Gambia before and after mass drug administration
  103. Structure‐Activity Studies of Truncated Latrunculin Analogues with Antimalarial Activity
  104. Epitope masking may limit antibody boosting to malaria vaccines
  105. Improving the quality of maternal and newborn care in the Pacific region: A scoping review
  106. Retargeting azithromycin analogues to have dual-modality antimalarial activity
  107. Antibody responses to a suite of novel serological markers for malaria surveillance demonstrate strong correlation with clinical and parasitological infection across seasons and transmission settings in The Gambia
  108. Evaluation of the effectiveness of topical repellent distributed by village health volunteer networks against Plasmodium spp. infection in Myanmar: A stepped-wedge cluster randomised trial
  109. Identifying and combating the impacts of COVID-19 on malaria
  110. Author Correction: Antibody responses to the RTS,S/AS01E vaccine and Plasmodium falciparum antigens after a booster dose within the phase 3 trial in Mozambique
  111. Antibody responses to a suite of novel serological markers for malaria surveillance demonstrate strong correlation with clinical and parasitological infection across seasons and transmission settings in The Gambia
  112. Impact of a rapid decline in malaria transmission on antimalarial IgG subclasses and avidity
  113. Iron Deficiency Is Associated With Reduced Levels of Plasmodium falciparum-specific Antibodies in African Children
  114. Antibody responses to the RTS,S/AS01E vaccine and Plasmodium falciparum antigens after a booster dose within the phase 3 trial in Mozambique
  115. High burden ofMycoplasma genitaliumand other reproductive tract infections among pregnant women in Papua New Guinea
  116. Th2-like T-follicular helper cells promote functional antibody production duringPlasmodium falciparuminfection
  117. Selection of Antibody Responses Associated With Plasmodium falciparum Infections in the Context of Malaria Elimination
  118. Sero-epidemiological evaluation of malaria transmission in The Gambia before and after mass drug administration
  119. Multifunctional Antibodies Are Induced by the RTS,S Malaria Vaccine and Associated With Protection in a Phase 1/2a Trial
  120. Strengthening routine immunization in Papua New Guinea: a cross-sectional provincial assessment of front-line services
  121. Multi-functional antibodies are induced by the RTS,S malaria vaccine and associated with protection in a phase I/IIa trial
  122. Strengthening routine immunization in Papua New Guinea: a cross-sectional provincial assessment of front-line services.
  123. Complement in malaria immunity and vaccines
  124. Novel particles for malaria vaccines
  125. IgM in human immunity to Plasmodium falciparum malaria
  126. Display of malaria transmission-blocking antigens on chimeric duck hepatitis B virus-derived virus-like particles produced in Hansenula polymorpha
  127. Induction and Kinetics of Complement-Fixing Antibodies Against Plasmodium vivax Merozoite Surface Protein 3α and Relationship With Immunoglobulin G Subclasses and Immunoglobulin M
  128. RTS,S/AS01E immunization increases antibody responses to vaccine-unrelated Plasmodium falciparum antigens associated with protection against clinical malaria in African children: a case-control study
  129. Iron deficiency, malaria, and low birth weight.
  130. Antibody Reactivity to Merozoite Antigens in Ghanaian Adults Correlates With Growth Inhibitory Activity Against Plasmodium falciparum in Culture
  131. Contribution of Functional Antimalarial Immunity to Measures of Parasite Clearance in Therapeutic Efficacy Studies of Artemisinin Derivatives
  132. Malaria vaccine candidates displayed on novel virus-like particles are immunogenic and induce transmission-blocking activity
  133. Display of malaria transmission-blocking antigens on chimeric duck hepatitis B virus-derived virus-like particles produced inHansenula polymorpha
  134. Differential Patterns of IgG Subclass Responses to Plasmodium falciparum Antigens in Relation to Malaria Protection and RTS,S Vaccination
  135. Dendritic Cell Responses and Function in Malaria
  136. Hepatitis B virus-like particles expressing Plasmodium falciparum epitopes induce complement-fixing antibodies against the circumsporozoite protein
  137. The salt between the beans: a qualitative study of the role of auxiliary midwives in a hard-to-reach area of Myanmar
  138. Understanding how the RTS,S malaria vaccine works
  139. Sulphadoxine-pyrimethamine plus azithromycin may improve birth outcomes through impacts on inflammation and placental angiogenesis independent of malarial infection
  140. Priority use cases for antibody-detecting assays of recent malaria exposure as tools to achieve and sustain malaria elimination
  141. Targeting malaria parasite invasion of red blood cells as an antimalarial strategy
  142. Targets of complement-fixing antibodies in protective immunity against malaria
  143. Different Life Cycle Stages of Plasmodium falciparum Induce Contrasting Responses in Dendritic Cells
  144. The impact of early life exposure to Plasmodium falciparum on the development of naturally acquired immunity to malaria in young Malawian children
  145. Antibody Responses to Antigenic Targets of Recent Exposure Are Associated With Low-Density Parasitemia in Controlled Human Plasmodium falciparum Infections
  146. Understanding transmission-blocking immunity compared to clinical immunity in malaria
  147. Challenges and strategies for developing efficacious and long-lasting malaria vaccines
  148. KILchip v1.0: A Novel Plasmodium falciparum Merozoite Protein Microarray to Facilitate Malaria Vaccine Candidate Prioritization
  149. Effectiveness of repellent delivered through village health volunteers on malaria incidence in villages in South-East Myanmar: a stepped-wedge cluster-randomised controlled trial protocol
  150. Loss of complement regulatory proteins on uninfected erythrocytes in vivax and falciparum malaria anemia
  151. Acquisition of Antibodies Against Endothelial Protein C Receptor–Binding Domains of Plasmodium falciparum Erythrocyte Membrane Protein 1 in Children with Severe Malaria
  152. Multiple morbidities in pregnancy: Time for research, innovation, and action
  153. Iron deficiency in pregnancy and poor birth outcomes
  154. Dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria during pregnancy and risk of malaria in early childhood: A randomized controlled trial
  155. Cellular dissection of malaria parasite invasion of human erythrocytes using viable Plasmodium knowlesi merozoites
  156. Factors influencing the induction of high affinity antibodies to Plasmodium falciparum merozoite antigens and how affinity changes over time
  157. Optimization of incubation conditions of Plasmodium falciparum antibody multiplex assays to measure IgG, IgG1–4, IgM and IgE using standard and customized reference pools for sero-epidemiological and vaccine studies
  158. The Complement System Contributes to Functional Antibody-Mediated Responses Induced by Immunization withPlasmodium falciparumMalaria Sporozoites
  159. Mechanism of immunity to malaria - blocking sporozoite infection
  160. Overcoming antigenic diversity of malaria vaccine candidates for better protection
  161. Proteome-wide mapping of immune features onto Plasmodium protein three-dimensional structures
  162. Combating low birth weight due to malaria infection in pregnancy.
  163. Effect of nutrient supplementation on the acquisition of humoral immunity to Plasmodium falciparum in young Malawian children
  164. Establishment of a yeast-based VLP platform for antigen presentation
  165. Antibodies generated by a vaccine against malaria in pregnancy
  166. The potential of task shifting selected maternal interventions to auxiliary midwives in Myanmar: a mixed-method study
  167. Immunity to severe malaria in children
  168. Sero-catalytic and Antibody Acquisition Models to Estimate Differing Malaria Transmission Intensities in Western Kenya
  169. Functional Conservation of the AMA1 Host-Cell Invasion Ligand Between P. falciparum and P. vivax: A Novel Platform to Accelerate Vaccine and Drug Development
  170. Impaired placental autophagy in placental malaria
  171. P. falciparum infection and maternofetal antibody transfer in malaria-endemic settings of varying transmission
  172. Identifying Immune Correlates of Protection Against Plasmodium falciparum Through a Novel Approach to Account for Heterogeneity in Malaria Exposure
  173. Understanding how immunity to malaria develops in children
  174. Identifying new drugs against malaria
  175. Acquisition, maintenance and adaptation of invasion inhibitory antibodies against Plasmodium falciparum invasion ligands involved in immune evasion
  176. The establishment of a WHO Reference Reagent for anti-malaria (Plasmodium falciparum) human serum
  177. Declining Transmission and Immunity to Malaria and Emerging Artemisinin Resistance in Thailand: A Longitudinal Study
  178. Dichotomous miR expression and immune responses following primary blood-stage malaria
  179. Impact of declining malaria transmission on human immunity
  180. The exported chaperone Hsp70-x supports virulence functions for Plasmodium falciparum blood stage parasites
  181. Host age and expression of genes involved in red blood cell invasion in Plasmodium falciparum field isolates
  182. Determinants of knowledge of critical danger signs, safe childbirth and immediate newborn care practices among auxiliary midwives: a cross sectional survey in Myanmar
  183. Prevention of postpartum haemorrhage by community-based auxiliary midwives in hard-to-reach areas of Myanmar: a qualitative inquiry into acceptability and feasibility of task shifting
  184. Antibody Responses to Plasmodium falciparum and Plasmodium vivax and Prospective Risk of Plasmodium spp. Infection Postpartum
  185. Host immunity to Plasmodium falciparum and the assessment of emerging artemisinin resistance in a multinational cohort
  186. The potential benefit of scaling up malaria prevention to reduce low birth weight in Africa
  187. Plasmodium vivax vaccine research – we’ve only just begun
  188. Inhibition of placental mTOR signaling provides a link between placental malaria and reduced birthweight
  189. Truncated Latrunculins as Actin Inhibitors Targeting Plasmodium falciparum Motility and Host Cell Invasion
  190. Evaluating Complement-Mediated Humoral Immunity to P. falciparum Blood Stages
  191. Differing rates of antibody acquisition in malaria: implications for immunity and surveillance
  192. Association between malaria immunity and pregnancy outcomes among Malawian pregnant women receiving nutrient supplementation
  193. Functional Antibodies and Protection against Blood-stage Malaria
  194. A malaria vaccine in children with HIV
  195. Structure–Activity Studies of β-Hairpin Peptide Inhibitors of the Plasmodium falciparum AMA1–RON2 Interaction
  196. A novel approach to identifying patterns of human invasion-inhibitory antibodies guides the design of malaria vaccines incorporating polymorphic antigens
  197. Specific antibodies to the PfRH5 invasion complex and protection from malaria
  198. Antibody responses to Plasmodium falciparum and Plasmodium vivax blood-stage and sporozoite antigens in the postpartum period
  199. The global threat of Zika virus to pregnancy: epidemiology, clinical perspectives, mechanisms, and impact
  200. Infectivity of Plasmodium falciparum in Malaria-Naive Individuals Is Related to Knob Expression and Cytoadherence of the Parasite
  201. A single point in protein trafficking by Plasmodium falciparum determines the expression of major antigens on the surface of infected erythrocytes targeted by human antibodies
  202. Merozoite Antigens of Plasmodium falciparum Elicit Strain-Transcending Opsonizing Immunity
  203. Strain-transcending immune response generated by chimeras of the malaria vaccine candidate merozoite surface protein 2
  204. Maternal-foetal transfer of Plasmodium falciparum and Plasmodium vivax antibodies in a low transmission setting
  205. Contrasting Patterns of Serologic and Functional Antibody Dynamics to Plasmodium falciparum Antigens in a Kenyan Birth Cohort
  206. Merozoite surface proteins in red blood cell invasion, immunity and vaccines against malaria
  207. Immunity to malaria in an era of declining malaria transmission
  208. High resolution FTIR imaging provides automated discrimination and detection of single malaria parasite infected erythrocytes on glass
  209. Designing malaria vaccines to circumvent antigen variability
  210. Erratum to: CD14 hi CD16+ monocytes phagocytose antibody-opsonised Plasmodium falciparum infected erythrocytes more efficiently than other monocyte subsets, and require CD16 and complement to do so
  211. Insights into the Immunological Properties of Intrinsically Disordered Malaria Proteins Using Proteome Scale Predictions
  212. Malaria and Age Variably but Critically Control Hepcidin Throughout Childhood in Kenya
  213. Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases
  214. Novel serologic biomarkers provide accurate estimates of recent Plasmodium falciparum exposure for individuals and communities
  215. Malaria eradication and elimination: views on how to translate a vision into reality
  216. Macrolides rapidly inhibit red blood cell invasion by the human malaria parasite, Plasmodium falciparum
  217. CD14hiCD16+ monocytes phagocytose antibody-opsonised Plasmodium falciparum infected erythrocytes more efficiently than other monocyte subsets, and require CD16 and complement to do so
  218. Differences in affinity of monoclonal and naturally acquired polyclonal antibodies against Plasmodium falciparum merozoite antigens
  219. Acquisition of Functional Antibodies That Block the Binding of Erythrocyte-Binding Antigen 175 and Protection AgainstPlasmodium falciparumMalaria in Children
  220. The impact of lipid-based nutrient supplementation on anti-malarial antibodies in pregnant women in a randomized controlled trial
  221. Maximizing antimalarial efficacy and the importance of dosing strategies
  222. Plasmodium vivax Malaria
  223. Risk factors for malaria and adverse birth outcomes in a prospective cohort of pregnant women resident in a high malaria transmission area of Papua New Guinea
  224. Conformational Dynamics and Antigenicity in the Disordered Malaria Antigen Merozoite Surface Protein 2
  225. Malaria and immunity during pregnancy and postpartum: a tale of two species
  226. Human Antibodies Fix Complement to Inhibit Plasmodium falciparum Invasion of Erythrocytes and Are Associated with Protection against Malaria
  227. PfRH5 as a candidate vaccine for Plasmodium falciparum malaria
  228. Acquisition of Antibodies against Plasmodium falciparum Merozoites and Malaria Immunity in Young Children and the Influence of Age, Force of Infection, and Magnitude of Response
  229. Research priorities for the development and implementation of serological tools for malaria surveillance
  230. Limited antigenic diversity of Plasmodium falciparumapical membrane antigen 1 supports the development of effective multi-allele vaccines
  231. Immunological markers of Plasmodium vivaxexposure and immunity: a systematic review and meta-analysis
  232. Use of Immunodampening To Overcome Diversity in the Malarial Vaccine Candidate Apical Membrane Antigen 1
  233. PTEX is an essential nexus for protein export in malaria parasites
  234. Opsonic phagocytosis of Plasmodium falciparummerozoites: mechanism in human immunity and a correlate of protection against malaria
  235. Decreasing Malaria Prevalence and Its Potential Consequences for Immunity in Pregnant Women
  236. Surface antigens of Plasmodium falciparum-infected erythrocytes as immune targets and malaria vaccine candidates
  237. A critical evaluation of pyrrolo[2,3-d]pyrimidine-4-amines as Plasmodium falciparum apical membrane antigen 1 (AMA1) inhibitors
  238. Subclass responses and their half-lives for antibodies against EBA175 and PfRh2 in naturally acquired immunity against Plasmodium falciparum malaria
  239. Overcoming Antigenic Diversity by Enhancing the Immunogenicity of Conserved Epitopes on the Malaria Vaccine Candidate Apical Membrane Antigen-1
  240. Sequential Processing of Merozoite Surface Proteins during and after Erythrocyte Invasion by Plasmodium falciparum
  241. Implications of the licensure of a partially efficacious malaria vaccine on evaluating second-generation vaccines
  242. Antibodies to Polymorphic Invasion-Inhibitory and Non-Inhibitory Epitopes of Plasmodium falciparum Apical Membrane Antigen 1 in Human Malaria
  243. Erythrocyte-Binding Antigens ofPlasmodium falciparumAre Targets of Human Inhibitory Antibodies and Function To Evade Naturally Acquired Immunity
  244. Identification and Prioritization of Merozoite Antigens as Targets of Protective Human Immunity to Plasmodium falciparum Malaria for Vaccine and Biomarker Development
  245. Acquired Antibodies to Merozoite Antigens in Children from Uganda with Uncomplicated or Severe Plasmodium falciparum Malaria
  246. Reply to Eisenhut
  247. PfEMP1 as a target of human immunity and a vaccine candidate against malaria
  248. Does Malaria Affect Placental Development? Evidence from In Vitro Models
  249. Defining the Timing of Action of Antimalarial Drugs against Plasmodium falciparum
  250. New approaches to studying Plasmodium falciparum merozoite invasion and insights into invasion biology
  251. Platelet Factor 4 and Duffy Antigen Required for Platelet Killing of Plasmodium falciparum
  252. Defining the Antigenic Diversity of Plasmodium falciparum Apical Membrane Antigen 1 and the Requirements for a Multi-Allele Vaccine against Malaria
  253. Antibody Boosting and Longevity Following Tetanus Immunization During Pregnancy
  254. The Plasmodium falciparum Erythrocyte Invasion Ligand Pfrh4 as a Target of Functional and Protective Human Antibodies against Malaria
  255. Antigenic Characterization of an Intrinsically Unstructured Protein, Plasmodium falciparum Merozoite Surface Protein 2
  256. New Insights into Acquisition, Boosting, and Longevity of Immunity to Malaria in Pregnant Women
  257. Targets of antibodies against Plasmodium falciparum–infected erythrocytes in malaria immunity
  258. Malaria Parasite Signal Peptide Peptidase is an ER‐Resident Protease Required for Growth but not for Invasion
  259. Plasmodium vivax Adherence to Placental Glycosaminoglycans
  260. Perspectives: The missing pieces
  261. Intermittent Preventive Treatment for Malaria in Papua New Guinean Infants Exposed to Plasmodium falciparum and P. vivax: A Randomized Controlled Trial
  262. High Affinity Antibodies to Plasmodium falciparum Merozoite Antigens Are Associated with Protection from Malaria
  263. Antibody to P. falciparum in Pregnancy Varies with Intermittent Preventive Treatment Regime and Bed Net Use
  264. Quantifying the Importance of MSP1-19 as a Target of Growth-Inhibitory and Protective Antibodies against Plasmodium falciparum in Humans
  265. A Phase 1 Trial of MSP2-C1, a Blood-Stage Malaria Vaccine Containing 2 Isoforms of MSP2 Formulated with Montanide® ISA 720
  266. Discovery of GAMA, a Plasmodium falciparum Merozoite Micronemal Protein, as a Novel Blood-Stage Vaccine Candidate Antigen
  267. IgG against Plasmodium falciparum variant surface antigens and growth inhibitory antibodies in Mozambican children receiving intermittent preventive treatment with sulfadoxine-pyrimethamine
  268. Antibodies to a Full-Length VAR2CSA Immunogen Are Broadly Strain-Transcendent but Do Not Cross-Inhibit Different Placental-Type Parasite Isolates
  269. Intermittent Preventive Treatment to Reduce the Burden of Malaria in Children: New Evidence on Integration and Delivery
  270. Placental Malaria-Associated Inflammation Disturbs the Insulin-like Growth Factor Axis of Fetal Growth Regulation
  271. Super-Resolution Dissection of Coordinated Events during Malaria Parasite Invasion of the Human Erythrocyte
  272. Reticulocyte and Erythrocyte Binding-Like Proteins Function Cooperatively in Invasion of Human Erythrocytes by Malaria Parasites
  273. Evidence That the Erythrocyte Invasion Ligand PfRh2 is a Target of Protective Immunity against Plasmodium falciparum Malaria
  274. Stepwise dissection of Plasmodium falciparum merozoite invasion of the human erythrocyte
  275. Association between Naturally Acquired Antibodies to Erythrocyte‐Binding Antigens ofPlasmodium falciparumand Protection from Malaria and High‐Density Parasitemia
  276. Minimal Association of Common Red Blood Cell Polymorphisms with Plasmodium falciparum Infection and Uncomplicated Malaria in Papua New Guinean School Children
  277. Complement receptor 1 is the host erythrocyte receptor for Plasmodium falciparum PfRh4 invasion ligand
  278. Isolation of viable Plasmodium falciparum merozoites to define erythrocyte invasion events and advance vaccine and drug development
  279. Interactions with heparin-like molecules during erythrocyte invasion by Plasmodium falciparum merozoites
  280. Using an Improved Phagocytosis Assay to Evaluate the Effect of HIV on Specific Antibodies to Pregnancy-Associated Malaria
  281. Antibodies to Chondroitin Sulfate A–Binding Infected Erythrocytes: Dynamics and Protection during Pregnancy in Women Receiving Intermittent Preventive Treatment
  282. Immunization with VAR2CSA-DBL5 Recombinant Protein Elicits Broadly Cross-Reactive Antibodies to Placental Plasmodium falciparum-Infected Erythrocytes
  283. Evaluation of the Antigenic Diversity of Placenta-Binding Plasmodium falciparum Variants and the Antibody Repertoire among Pregnant Women
  284. The Relationship between Anti-merozoite Antibodies and Incidence of Plasmodium falciparum Malaria: A Systematic Review and Meta-analysis
  285. Development of fluorescent Plasmodium falciparum for in vitro growth inhibition assays
  286. Strain-Specific Duffy Binding Protein Antibodies Correlate with Protection against Infection with Homologous Compared to Heterologous Plasmodium vivax Strains in Papua New Guinean Children
  287. The future for blood‐stage vaccines against malaria
  288. Cellular Tumor Necrosis Factor, Gamma Interferon, and Interleukin-6 Responses as Correlates of Immunity and Risk of Clinical Plasmodium falciparum Malaria in Children from Papua New Guinea
  289. Sir2 Paralogues Cooperate to Regulate Virulence Genes and Antigenic Variation in Plasmodium falciparum
  290. Antibodies to Reticulocyte Binding Protein-Like Homologue 4 Inhibit Invasion of Plasmodium falciparum into Human Erythrocytes
  291. Reticulocyte-binding protein homologue 5 – An essential adhesin involved in invasion of human erythrocytes by Plasmodium falciparum
  292. Immunoglobulin G Subclass-Specific Responses against Plasmodium falciparum Merozoite Antigens Are Associated with Control of Parasitemia and Protection from Symptomatic Illness
  293. Analysis of structure and function of the giant protein Pf332 in Plasmodium falciparum
  294. Recent insights into humoral and cellular immune responses against malaria
  295. Acquisition of Growth-Inhibitory Antibodies against Blood-Stage Plasmodium falciparum
  296. Antibody-Mediated Growth Inhibition of Plasmodium falciparum: Relationship to Age and Protection from Parasitemia in Kenyan Children and Adults
  297. Exported Proteins Required for Virulence and Rigidity of Plasmodium falciparum-Infected Human Erythrocytes
  298. Estimating the Burden of Global Mortality in Children Aged <5 Years by Pathogen‐Specific Causes
  299. Characteristics of Plasmodium falciparum-Infected-Erythrocyte Adhesion to Chondroitin Sulfate
  300. Polymorphic and Conserved Targets of Antibodies againstPlasmodium falciparumduring Pregnancy
  301. Truncation of Plasmodium berghei merozoite surface protein 8 does not affect in vivo blood-stage development
  302. Quantification of penicillin G during labor and delivery by capillary electrophoresis
  303. Variation in use of erythrocyte invasion pathways by Plasmodium falciparum mediates evasion of human inhibitory antibodies
  304. Characterization of VAR2CSA-deficient Plasmodium falciparum-infected erythrocytes selected for adhesion to the BeWo placental cell line
  305. Towards a Vaccine against Plasmodium vivax Malaria
  306. Structural Basis for Binding of Plasmodium falciparum Erythrocyte Membrane Protein 1 to Chondroitin Sulfate and Placental Tissue and the Influence of Protein Polymorphisms on Binding Specificity
  307. Serum Lipoproteins Promote Efficient Presentation of the Malaria Virulence Protein PfEMP1 at the Erythrocyte Surface
  308. Antibodies among Men and Children to Placental-Binding Plasmodium falciparum-Infected Erythrocytes that Express var2csa
  309. THE RISK OF MALARIAL INFECTIONS AND DISEASE IN PAPUA NEW GUINEAN CHILDREN
  310. Skeleton-binding protein 1 functions at the parasitophorous vacuole membrane to traffic PfEMP1 to the Plasmodium falciparum–infected erythrocyte surface
  311. Development and Optimization of High-Throughput Methods To Measure Plasmodium falciparum-Specific Growth Inhibitory Antibodies
  312. Antigenic Differences and Conservation among PlacentalPlasmodium falciparum–Infected Erythrocytes and Acquisition of Variant‐Specific and Cross‐Reactive Antibodies
  313. A var gene promoter controls allelic exclusion of virulence genes in Plasmodium falciparum malaria
  314. Promising Functional Readouts of Immunity in a Blood-Stage Malaria Vaccine Trial
  315. Targets of Protective Antibodies to Malaria during Pregnancy
  316. Placental Malaria Induces Variant-Specific Antibodies of the Cytophilic Subtypes Immunoglobulin G1 (IgG1) and IgG3 That Correlate with Adhesion Inhibitory Activity
  317. Cross-Reactive Surface Epitopes on Chondroitin Sulfate A-Adherent Plasmodium falciparum-Infected Erythrocytes Are Associated with Transcription of var2csa
  318. Broad analysis reveals a consistent pattern of var gene transcription in Plasmodium falciparum repeatedly selected for a defined adhesion phenotype
  319. The Immunology and Pathogenesis of Malaria During Pregnancy
  320. Clinical features and pathogenesis of severe malaria
  321. Variable intrauterine pressure catheter (IUPC)tracings with two catheters
  322. Malaria in pregnancy and the endemicity spectrum: what can we learn?
  323. Impairment of humoral immunity to Plasmodium falciparum malaria in pregnancy by HIV infection
  324. Phenotypes of Plasmodium falciparum from the Peripheral Blood of Pregnant Women
  325. Antibodies to Variant Surface Antigens ofPlasmodium falciparum–Infected Erythrocytes and Adhesion Inhibitory Antibodies Are Associated with Placental Malaria and Have Overlapping and Distinct Targets
  326. Plasmodium falciparum–Infected Erythrocytes Demonstrate Dual Specificity for Adhesion to Hyaluronic Acid and Chondroitin Sulfate A and Have Distinct Adhesive Properties
  327. An alternative agglutination assay to measure antibodies to variant surfaceantigens of Plasmodium falciparum-infected erythrocytes
  328. Selective Accumulation of Mature Asexual Stages of Plasmodium falciparum-Infected Erythrocytes in the Placenta
  329. Evaluating specific adhesion of Plasmodium falciparum-infected erythrocytes to immobilised hyaluronic acid with comparison to binding of mammalian cells
  330. The Structural Motif in Chondroitin Sulfate for Adhesion ofPlasmodium falciparum-infected Erythrocytes Comprises Disaccharide Units of 4-O-Sulfated and Non-sulfated N-Acetylgalactosamine Linked to Glucuronic Acid
  331. Expanding the paradigms of placental malaria
  332. Pathogenesis of Plasmodium falciparum malaria: the roles of parasite adhesion and antigenic variation
  333. Parasite adhesion and immune evasion in placental malaria
  334. Sticky rings: challenging the cytoadherence dogma
  335. New agents to combat malaria
  336. Inhibition of Adhesion of Plasmodium falciparum-Infected Erythrocytes by Structurally Defined Hyaluronic Acid Dodecasaccharides
  337. Identification of Glycosaminoglycan Binding Domains in Plasmodium falciparum Erythrocyte Membrane Protein 1 of a Chondroitin Sulfate A-Adherent Parasite
  338. Plasmodium falciparum Rosette Formation Is Uncommon in Isolates from Pregnant Women
  339. Adhesion of Plasmodium falciparum-infected erythrocytes to hyaluronic acid in placental malaria
  340. The placenta in malaria: mechanisms of infection, disease and foetal morbidity
  341. The placenta in malaria: mechanisms of infection, disease and foetal morbidity
  342. Plasmodium falciparumIsolates from Infected Pregnant Women and Children Are Associated with Distinct Adhesive and Antigenic Properties
  343. The adhesion ofPlasmodium falciparum-infected erythrocytes to chondroitin sulfate A is mediated byP. falciparumerythrocyte membrane protein 1
  344. 2′-Fluoropyrimidine RNA-based Aptamers to the 165-Amino Acid Form of Vascular Endothelial Growth Factor (VEGF165)
  345. Inhibition of Binding of Malaria-Infected Erythrocytes by a Tetradecasaccharide Fraction from Chondroitin Sulfate A
  346. Age and damage induced changes in amyloid protein precursor immunohistochemistry in the rat brain
  347. Differential distribution of amyloid protein precursor immunoreactivity in the rat brain studied by using five different antibodies
  348. Synthesis and transacylating reactivity of β-cyclodextrin ethylenediamines